Atazanavir (Reytaz) is indicated to treat patients with an HIV-1 infection.
Teva Pharmaceutical Industries recently announced the launch of a generic version of atazanavir (Reyataz) capsules, according to a company press release.
Atazanir sulfate is a protease inhibitor approved as part of a combination of antiretroviral drugs for HIV-positive patients 6 years and older.
In clinical trials, approximately 20% of patients treated with atazanavir sulfate developed a rash. Teva reported that some patients also developed Stevens-Johnson syndrome, erythema multiforme, and toxic skin eruptions, according to the press release.
Additionally, the most common adverse reactions include nausea, jaundice/scleral icterus, rash, headache, abdominal pain, vomiting, insomnia, peripheral neurologic symptoms, dizziness, myalgia, diarrhea, depression, and fever, according to the release.
Teva said that Rayataz had sales of $402 million in the United States, as indicated by October 2017 IMS data.
The launch of the generic drug may increase patient access to low-cost antiviral treatment and help prevent the spread of HIV, according to the release.
“The exclusive launch of our generic version of Reyataz marks our fifth generic product offering for the treatment of HIV-1 infection,” said Brendan O’Grady, executive vice president, North America Commercial at Teva. “Antiviral medications continue to be a focus for Teva Generics, and this is an important addition to our portfolio.”